retatrutide triple hormone receptor agonist metabolic obesity Mazdutide vs retatrutide: dual meets agonist in the next-gen weight loss showdown Substack Series 3 of 6:

Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis

No contraindication multi-select, no MTC/MEN2, no pancreatitis, no pregnancy, no eating disorder, no medication or allergy capture

If you hit a plateau on three times weekly dosing, returning to daily dosing is a reasonable first step before escalating the dose

If youre considering compounded semaglutide, make sure to discuss your options with a licensed healthcare provider you trust

Retatrutide is a protein-based molecule that degrades under improper conditions

Side Effects: What to Expect from Each Medication Foundayo Side Effects Common (occurring most often during dose escalation): Nausea Constipation Diarrhea Vomiting Indigestion / abdominal pain Hair loss (noted more than with injectable GLP-1s) Discontinuation due to adverse events: 5.310.3% depending on dose, vs 2.7% placebo (ATTAIN-1)